AnaptysBio, Inc.
ANAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $376 | $577 | $873 | $953 |
| - Cash | $123 | $36 | $71 | $496 |
| + Debt | $369 | $18 | $19 | $21 |
| Enterprise Value | $622 | $559 | $821 | $478 |
| Revenue | $91 | $17 | $10 | $63 |
| % Growth | 432% | 66.8% | -83.7% | – |
| Gross Profit | -$73 | -$115 | -$79 | -$35 |
| % Margin | -79.5% | -671% | -763.2% | -55.9% |
| EBITDA | -$93 | -$156 | -$105 | -$56 |
| % Margin | -101.6% | -911.7% | -1,023.2% | -88.2% |
| Net Income | -$145 | -$164 | -$129 | -$58 |
| % Margin | -159.1% | -953.7% | -1,251.3% | -91.5% |
| EPS Diluted | -5.12 | -6.08 | -4.57 | -2.11 |
| % Growth | 15.8% | -33% | -116.6% | – |
| Operating Cash Flow | -$135 | -$121 | -$74 | -$46 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$1 |
| Free Cash Flow | -$136 | -$122 | -$74 | -$47 |